Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma

NCT03682276 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab

Sponsor

Imperial College London

Collaborators

[object Object]